Comparative efficacy, toxicity and biodistribution of the liposomal amphotericin B formulations Fungisome®and AmBisome®in murine cutaneous leishmaniasis

• Authors: Wijnant GJ, Van Bocxlaer K, Yardley V, Harris A, Alavijeh M, Silva-Pedrosa R, Antunes S, Maurício I, Murdan S, Croft SL
• Publication Year: 2018
• Journal: International Journal for Parasitology: Drugs and Drug Resistance
• Link: https://www.ncbi.nlm.nih.gov/pubmed/29673889

Fungisome® (F), a liposomal amphotericin B (AmB) product, is marketed in India as a safe and effective therapeutic for the parasitic infection visceral leishmaniasis. Its potential in the treatment of cutaneous leishmaniasis (CL), a disfiguring form of the disease affecting the skin, is currently unknown. Here, we report the evaluation of the efficacy of F in […]
Read More